Hilde Marie Torgauten

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

Marton König, Hilde Marie Torgauten, The Trung Tran et al. · JAMA Neurology · 2022 · 84 citations · Full text

Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

Marton König, Åslaug Rudjord Lorentzen, Hilde Marie Torgauten et al. · Journal of Neurology Neurosurgery & Psychiatry · 2021 · 54 citations · Full text

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study

Hilde Marie Torgauten, Kjell‐Morten Myhr, Stig Wergeland et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 2021 · 38 citations · Full text

Predictors of hospitalization due to infection in rituximab-treated MS patients

Jakob Rishovd Karlowicz, Mattias Klakegg, Jan Aarseth et al. · Multiple Sclerosis and Related Disorders · 2023 · 12 citations · Full text